| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Genetic Markers for Aggressive Head and Neck Cancer Identified BRONX, NY -- March 18, 2009 -- Researchers have identified genetic markers that signal poor outcomes for patients with head and neck cancer, according to a study published in the March issue of the American Journal of Pathology. The findings could one day lead to a genetic test that could help select or predict successful treatment options for patients with this type of cancer. Richard Smith, MD, Albert Einstein College of Medicine at Yeshiva University, and Montefiore Medical Center, Bronx, New York, and colleagues analysed samples from 104 patients with head and neck cancer who were treated at Montefiore Medical Center. The patients were treated and followed over 5 years. At the time of cancer diagnosis and before any therapy, researchers removed samples tumour tissue from patients, as well as normal tissue adjacent to their tumour, and measured microRNA levels in the 2 types of tissue. Patients who fared worst had the lowest levels of miR-205 and let-7d in their tumour tissue. Specifically, these patients were 4 times more likely to have an earlier metastasis or local-regional recurrence of their cancer than patients with higher levels of miR-205 and let-7. "A biologic marker identifying aggressive tumours would allow us to direct therapy more appropriately, minimising over or under-treatment," said Dr. Smith. "Our next steps are to confirm these results in a new patient population and to find additional markers that would allow us to develop a reproducible and accurate prognostic test," said senior author Nicolas Schlecht, PhD, Albert Einstein College of Medicine. SOURCE: Albert Einstein College of Medicine of Yeshiva University
|